Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated W...
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
About this item
Full title
Author / Creator
Sanda, Gregory E , Shabto, Julie M , Goyal, Subir , Liu, Yuan , Martini, Dylan J , Nazha, Bassel , Brown, Jacqueline T , Yantorni, Lauren B , Anne Russler, Greta , Caulfield, Sarah , Joshi, Shreyas S , Narayan, Vikram M , Kissick, Haydn , Ogan, Kenneth , Master, Viraj A , Carthon, Bradley C , Kucuk, Omer and Bilen, Mehmet Asim
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Background
In advanced urothelial cancers (UC), immune checkpoint inhibitors (ICI) show promise as a durable therapy. Immune-related adverse events (irAEs), a side effect of ICIs, may serve as an indicator of beneficial response. We investigated the relationship between irAEs and clinical outcomes in patients with advanced UC who received ICI.
Alternative Titles
Full title
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10712712
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10712712
Other Identifiers
ISSN
1083-7159,1549-490X
E-ISSN
1549-490X
DOI
10.1093/oncolo/oyad154
